Taiwan Precision Medicine Study on Advanced Non-Small-Cell Lung Cancer
Collecting Genetic Data and Treatment Outcomes to Improve Targeted Therapies
Led by National Health Research Institutes, Taiwan · Updated on 2026-04-08
550
Participants Needed
13
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Non-small-cell lung cancer NSCLC is one of the top three most common cancers in Taiwan, with a higher prevalence of targetable genetic mutations in Asian populations compared to Western populations. This research aims to create a national, multi-center, population-focused project to better understand the genetic and clinical characteristics of advanced NSCLC patients, especially those with wild-type EGFRALK or resistant to tyrosine kinase inhibitors TKIs. The study seeks to improve treatment selection and extend overall survival by integrating genetic and clinical data.
The study plans to enroll 550 patients with advanced NSCLC to undergo next-generation sequencing NGS analysis on tumor tissue samples. This will include treatment-nafve patients and those refractory to TKIs. Researchers will collect tumor samples, perform large-scale genetic profiling, and record prior treatments, responses, and side effects. The goal is to map genetic features related to drug resistance and identify new treatment approaches.
Participants will provide tumor tissue samples and medical history data, which will be stored in an integrated database alongside clinical and treatment outcome information. Follow-up and regular assessments will be conducted to monitor therapeutic responses and adverse events. The primary outcome is the development of a comprehensive genetic map from 2021 to 2030 to support personalized medicine and suitable clinical trials for NSCLC patients in Taiwan.
CONDITIONS
Brief Title
The Research Plan of Taiwan Precision Medicine
Research Team
Y
Ya-Ling Wu
N
Nai-Jung Chiang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Pathological diagnosis of adenocarcinoma, squamous cell carcinoma, large cell carcinoma, adenosquamous carcinoma, or sarcomatoid carcinoma.
For squamous cell carcinoma patients, only never smokers or light smokers (less than 10 cigarettes per day) are eligible.
For advanced EGFR/ALK-negative adenocarcinoma or other histological types, treatment-nafve or failure to two or fewer lines of systemic treatment is allowed.
For advanced EGFR/ALK-positive adenocarcinoma, failure to two or fewer lines of systemic treatment, including tyrosine kinase inhibitors, is allowed.
For advanced EGFR exon 20 insertion/mutation (excluding T790M mutation) adenocarcinoma, failure to four or fewer lines of systemic treatment, including tyrosine kinase inhibitors, is allowed.
Ability to provide tumor tissue after previous treatment failure.
Willingness to provide residual biopsy or operative slides.
Life expectancy of more than 3 months.
Understanding of the protocol and willingness for regular follow-up.
For EGFR exon 20 insertion/mutation adenocarcinoma patients who died before July 31, 2022, waiver of informed consent may apply with ethics approval.
You will not qualify if you...
Inability to provide a complete medical history.
No available tumor tissue for genetic testing.
Poor compliance or unwillingness to follow study procedures.
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Diagnostic Evaluation
Duration - May 2021 to December 2030
Participants provide tumor samples and clinical information for large-scale genetic analysis to understand drug resistance mechanisms and identify new treatment strategies.
1 visit to provide tumor tissue and medical history
Long-term Monitoring
Duration - Up to 9 years
Participants are followed regularly to record previous treatments, treatment responses, and adverse events over time.
Regular follow-up visits as per protocol
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Study of BMS-986340 Alone and With Nivolumab, Docetaxel, or Pumitamig in Adults With Advanced Solid Tumors
Study of ASP5834 to Find Suitable Doses and Evaluate Safety in Adults With Advanced Solid Tumors Having KRAS Mutations or Amplifications
Study of SHR-1316 Antibody or Placebo with Chemotherapy for Treating Resectable Stage II or III Non-Small Cell Lung Cancer
Phase IIIII Study of Andamertinib With or Without Platinum Chemotherapy Compared to Platinum Chemotherapy Alone in Adults With Advanced Non-Squamous NSCLC Having Atypical EGFR Mutations
Phase 1 Trial of Personalized Neoantigen-Primed Dendritic Cell Vaccine After Surgery for Advanced Gastric, Liver, Lung, and Colorectal Cancers
Phase II Study of TQB2450 Injection With Anlotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer After First-Line Immunotherapy Failure
Study of Stereotactic Radiation Therapy Combined With Anlotinib for Treating Brain Metastases in Non-Small Cell Lung Cancer Patients
Global Phase 3 Study Comparing Firmonertinib With Investigator-Selected EGFR Inhibitors
for First-Line Treatment of Advanced or Metastatic NSCLC with EGFR PACC Mutations
Taiwan Precision Medicine Study on Advanced Non-Small-Cell Lung Cancer
Collecting Genetic Data and Treatment Outcomes to Improve Targeted Therapies
Evaluation of Vebreltinib Combined with Furmonertinib as First Treatment for Advanced Non-Small Cell Lung Cancer with EGFR Mutations and High PD-L1 Expression
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Registry of Genetic Alterations of Taiwan Non-Small Cell Lung Cancer by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study-Taiwan Cooperative Oncology Group T1521.